🎯 Target the Brain, Ignore Insulin? Why the New Obesity Roadmap Might Be Missing the Mark

“Appetite is in the brain.” But what if the fire isn’t just in the wiring—it’s in the fuel?

A recent Cell review published on August 7, 2025, is causing a stir in the obesity research and clinical community. Titled "The Neurobiology of Obesity: Implications for Next-Generation Therapeutics," the paper offers a sweeping synthesis of the latest science on obesity as a brain-centered disease, drawing from genetics, neuroendocrinology, and pharmacology.

It paints a compelling picture—obesity as the result of misfiring hypothalamic circuits, reward dysregulation, and synaptic maladaptation. The authors advocate for cutting-edge pharmaceutical solutions: GLP-1 receptor agonists (GLP-1RAs), dual and triple incretin agonists, and NMDA receptor modulators aimed at rewiring the brain’s hunger and satiety circuits.

And yet, this sophisticated narrative leaves one glaring issue almost entirely unaddressed:

What about insulin resistance? What about the food itself?

🧠 Obesity as a Brain Disorder: The Main Findings

The review's major takeaways include:

• Obesity risk is primarily encoded in the brain. Genome-wide association studies (GWAS) show that most BMI-related genes are expressed in brain areas controlling appetite and reward.

• GLP-1RAs and newer incretin-based therapies (e.g., tirzepatide, retatrutide) produce unprecedented weight loss by modulating brainstem satiety pathways.

• Neuroplasticity-based interventions, like NMDA receptor modulation, may offer long-term solutions by remodeling hunger circuits and preventing weight regain.

It’s an exciting frontier—but also a dangerously narrow one.

⚠️ The Blind Spot: Insulin, Ultra-Processed Food, and Metabolic Stress

The paper’s primary flaw?

It largely ignores the metabolic engine of obesity—chronic overnutrition, ultra-processed foods, and the resulting insulin resistance.

GLP-1-based drugs may reduce appetite, but if individuals continue to consume:

• High-glycemic, insulin-spiking foods,

• Industrial seed oils promoting inflammation,

• Nutrient-poor, calorie-dense diets,

…then the root cause of metabolic dysfunction remains unresolved.

In fact, insulin resistance itself is a protective adaptation—a signal that cells are already overloaded with energy. Suppressing appetite without addressing this overload may reduce weight temporarily but fail to reverse systemic metabolic stress.

🧬 Who Stands to Benefit? A Look at Conflicts of Interest

The review’s authors include founders of Ousia Pharma, a biotech company developing obesity drugs. Several are funded by the Novo Nordisk Foundation, affiliated with the makers of Ozempic and Wegovy—two dominant GLP-1 receptor agonists.

While the review is published in a high-impact journal and represents a valid scientific perspective, the financial ties to the pharmaceutical sector should be disclosed not only in fine print, but in how we interpret the framing of this “brain-based” solution to obesity.

This isn’t to dismiss their work—it’s to add essential context. When billions are at stake in the weight-loss drug market, scientific neutrality is harder to preserve.

🧩 A Systems-Based View: The ERM Perspective

In contrast, the Exposure-Related Malnutrition (ERM) framework proposes that obesity, aging, and chronic disease arise from bioenergetic overload and misallocation—not just brain misfiring.

• Appetite dysregulation is only one node in a network of stress-adaptation failures.

• Chronic insulin elevation drives inflammation, mitochondrial stress, and hormonal dysfunction.

• Simply suppressing hunger without restoring metabolic flexibility or addressing micronutrient depletion is, at best, a short-term fix.

Obesity cannot be fully understood—or treated—without integrating neurobiology, metabolic adaptation, nutrient quality, and environmental exposure.

🧠💉 Final Thoughts: A Cautionary Path

Brain-targeted therapies like GLP-1RAs have earned their place in the clinical toolkit. But the danger lies in overpromising and underexplaining—selling a story where the brain is to blame and the drug is the savior, while ignoring insulin, diet, and environment.

Let’s celebrate progress in neuroscience—but not forget the pancreas, the liver, the muscle, or the food system.

Because the real cure for obesity isn’t just in the mind—it’s in the metabolic roots beneath it.

If you're curious about alternative frameworks like ERM or how to restore metabolic resilience through lifestyle and nutrient-focused strategies, follow this blog or explore www.healingpassion-asia.com.

Clemmensen, C., Jørgensen, V. B. I., Pers, T. H., & Schwartz, M. W. (2025). The neurobiology of obesity: Implications for next-generation therapeutics. Cell, 186(16), 3347–3366. https://doi.org/10.1016/j.cell.2025.07.002

#Obesity neurobiology, #GLP-1 receptor agonists, #Insulin resistance, #Metabolic adaptation, #Conflict of interest in obesity research